Recombinant activated factor VII (eptacog alfa activated, NovoSeven ® ) in patients with rare congenital bleeding disorders. A systematic review on its use in surgical procedures

Current Pharmacological Design

11 January Jan 2017 one month ago
  • Myasoedova VA, Amato M, Tremoli E, Di Minno A.

In the absence of definite guidelines in the area, we have carried a systemic review to provide a thorough overview concerning the efficacy and safety of recombinant activated factor VII (rFVIIa, NovoSeven®, Novo Nordisk A/S, Bagsværd, Denmark) in patients with Glanzmann's thrombasthenia (GT) and FVII deficiency, undergoing surgical procedures.

Reference
Di Minno MN, Ambrosino P, Myasoedova VA, Amato M, Ventre I, Tremoli E, Di Minno A. Recombinant activated factor VII (eptacog alfa activated, NovoSeven ® ) in patients with rare congenital bleeding disorders. A systematic review on its use in surgical procedures. Curr Pharm Des 2016 Dec 30[Epub ahead of print]

Go to PubMed